Archives
Can a Native Milk Promoter Raise Pharming Yield?
2026-11-22
A 2025 rabbit study reported recombinant tdTomato concentrations of 15–20 g/L after targeted insertion at the endogenous CSN2 locus. The result supports a promising proof of concept for locus-aware animal pharming, but it does not yet establish general performance across therapeutic proteins, animals, or manufacturing workflows.
What High-Yield Rabbit Pharming Shows
2026-11-21
A targeted rabbit line produced a strikingly high reported milk concentration of a recombinant reporter protein, but the comparison does not yet separate promoter effects, genomic context, animal genotype, and protein-specific biology. The finding is best viewed as a strong proof of concept rather than a general estimate for therapeutic-protein production.
Why CSN2 Matters in Rabbit Pharming
2026-11-20
A literature-focused analysis of a 2025 study showing that targeted insertion of a reporter gene at the rabbit CSN2 locus produced substantially higher milk concentrations than historical pharming benchmarks. The findings support a promising proof of concept, while leaving important questions about therapeutic proteins, product quality, animal-to-animal variation, and manufacturing consistency.
Rabbit Pharming and the CSN2 Locus
2026-11-20
A literature-focused analysis of how targeted insertion at the rabbit CSN2 locus was used to raise recombinant protein concentration in milk, what the reported 15–20 g/L result establishes, and which biological and manufacturing questions remain open.
Targeted Promoters and High-Yield Rabbit Pharming
2026-11-19
A literature-focused analysis of how CSN2-locus targeting, endogenous promoter activity, and germline transmission shaped a reported increase in recombinant protein concentration in rabbit milk—along with the limits of the evidence.
Why the CSN2 Locus Raised Rabbit Pharming Yield
2026-11-18
A 2025 study links targeted insertion at the endogenous rabbit CSN2 locus with unusually high tdTomato concentrations in milk. The findings support a promoter-and-locus mechanism, while leaving important questions about construct-specific behavior, total production, biological activity, and generalizability to therapeutic proteins.
Context Is Part of the Yield Result
2026-11-18
A reported 15–20 g/L milk concentration is scientifically meaningful, but its interpretation depends on the reporter protein, genetic locus, animal genotype, comparator, and scale of measurement.
Why CSN2 Targeting Raises Rabbit Milk Output
2026-11-17
A targeted CSN2 strategy links genomic context, promoter activity, and transgene dosage to substantially higher recombinant-protein concentration in rabbit milk. The evidence is promising but remains centered on a fluorescent reporter, a small number of animals, and heterogeneous historical comparisons.
CSN2 Targeting and Rabbit Pharming Yield
2026-11-17
A 2025 study reports that placing a fluorescent reporter at the endogenous rabbit CSN2 locus produced substantially higher milk concentrations than those commonly reported for conventional transgenic rabbit lines. The result supports promoter and genomic-context effects as important determinants of pharming output, but the evidence remains limited by the small number of high-yield animals, the use of a reporter rather than a therapeutic protein, and the absence of a direct matched comparison within the reported study.
How a CSN2 Knock-In Raised Rabbit Milk Yield
2026-11-16
A 2025 study tested whether placing a reporter gene at the endogenous rabbit CSN2 locus could overcome the variable expression associated with conventional transgenic lines. The reported 15–20 g/L milk concentrations in two homozygous females are striking, but they represent an early proof of concept rather than evidence that every therapeutic protein will show comparable yield or function.
Why the CSN2 Locus Raises Rabbit Pharming Yield
2026-11-16
A mechanistic analysis of how endogenous milk-gene regulation, targeted integration and zygosity may explain the reported increase in recombinant protein concentration, alongside the limits of comparing a fluorescent reporter with therapeutic proteins.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-15
A critical reading of a 2025 study on targeted transgene placement in rabbits, explaining why its reported milk concentrations are promising while remaining a proof of concept rather than a general validation of therapeutic-protein production.
Why CSN2 Targeting Raises Rabbit Milk Yield
2026-11-14
A 2025 study links targeted insertion at the rabbit CSN2 locus with markedly increased reporter-protein concentrations in milk. The findings support a mechanistic model involving endogenous mammary regulation, genomic context and allele dosage, while leaving important questions about protein identity, reproducibility and therapeutic applicability unresolved.
Why Cytosolic crRNA Changes Cas13 Performance
2026-11-13
A 2025 study shows that promoter choice can alter where Cas13 guide RNAs accumulate and, consequently, which RNA-regulation functions are accessible. The findings support compartmental localization as a major determinant of Cas13 activity, while leaving open questions about transcript stability, cell-type generality, guide dependence and quantitative performance.
How a Native Milk Promoter Raises Pharming Yield
2026-11-13
An engineered rabbit line used targeted insertion at the CSN2 locus to couple a reporter gene to a native milk-protein regulatory context. The reported 15–20 g/L milk concentration is striking, but it is best interpreted as evidence for a locus-and-promoter strategy in a small, model-specific dataset—not as a general yield guarantee for therapeutic proteins.